Cardiol Therapeutics (CRDL) Upgraded to Buy: Here’s Why
ZacksCardiol Therapeutics (CRDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardiol Therapeutics (CRDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).